Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Surfactant Administration by Transient Intubation in Infants 29 to 35 Weeks' Gestation with Respiratory Distress Syndrome Decreases the Likelihood of Later Mechanical Ventilation: A Randomized Controlled Trial

Abstract

OBJECTIVE:

To assess, among premature infants with early respiratory distress syndrome (RDS), the effect of one dose of intratracheally administered surfactant followed by extubation to nasal continuous positive airway pressure (NCPAP) on subsequent mechanical ventilation (MV), when compared with NCPAP alone.

STUDY DESIGN:

Randomized, blinded trial in infants 29 to 35 weeks' gestation with mild-to-moderate RDS requiring supplemental oxygen and NCPAP. Infants were randomized to intubation, surfactant treatment, and immediate extubation (surfactant group N=52), or to no intervention (control group N=53). All infants were subsequently managed with NCPAP.

RESULTS:

Need for later MV was 70% in the control group and 50% in the surfactant group. Surfactant group subjects had lower inspired oxygen fraction (FiO2) after study intervention and were less likely to require subsequent surfactant. Overall surfactant use, duration of O2 therapy, length of stay, and bronchopulmonary dysplasia were unaffected.

CONCLUSION:

Among premature infants with mild-to-moderate RDS, transient intubation for surfactant administration reduces later MV.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Rodriguez RJ . Management of respiratory distress syndrome: an update. Respir Care 2003;48:279–287.

    PubMed  Google Scholar 

  2. Schimmel MS, Hammerman C . Early nasal continuous positive airway pressure with or without prophylactic surfactant therapy in the premature infant with respiratory distress syndrome. Pediatr Radiol 2000;30:713–714.

    Article  CAS  Google Scholar 

  3. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F . Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100:E4 (http://www.pediatrics.org/cgi/content/full/100/1/e4).

    Article  CAS  Google Scholar 

  4. Avery ME, Mead J . Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517–523.

    CAS  Google Scholar 

  5. Verder H, Robertson B, Greisen G et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish–Swedish Multicenter Study Group. N Engl J Med 1994;331:1051–1055.

    Article  CAS  Google Scholar 

  6. Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999;103:E24 (http://www.pediatrics.org/cgi/content/full/103/2/e24).

    Article  CAS  Google Scholar 

  7. Kendig JW, Notter RH, Cox C et al. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics 1988;82:756–762.

    CAS  PubMed  Google Scholar 

  8. Victorin LH, Deverajan LV, Curstedt T, Robertson B . Surfactant replacement in spontaneously breathing babies with hyaline membrane disease — a pilot study. Biol Neonate 1990;58:121–126.

    Article  CAS  Google Scholar 

  9. Long W, Corbet A, Cotton R, et al. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. N Engl J Med 1991;325:1696–1703.

    Article  CAS  Google Scholar 

  10. Alba J, Agarwal R, Hegyi T, Hiatt IM . Efficacy of surfactant therapy in infants managed with CPAP. Pediatr Pulm 1995;20:172–176.

    Article  CAS  Google Scholar 

  11. Soll RF . Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2003;1.

  12. Kattwinkel J, Bloom BT, Delmore P, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993;92:90–98.

    CAS  PubMed  Google Scholar 

  13. Dunn MS, Shennan AT, Zayack D, Possmayer F . Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991;87:377–386.

    CAS  PubMed  Google Scholar 

  14. Bevilacqua G, Halliday H, Parmigiani S, Robertson B . Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome. The Collaborative European Multicentre Study Group. J Perinat Med 1993;21:329–340.

    Article  CAS  Google Scholar 

  15. Bevilacqua G, Parmigiani S, Robertson B . Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial. J Perinat Med 1996;24:609–620.

    Article  CAS  Google Scholar 

  16. Jobe AH . Pulmonary surfactant therapy. N Engl J Med 1993;328:861–868.

    Article  CAS  Google Scholar 

  17. Lang MJ, Hall RT, Reddy NS, Kurth CG, Merritt TA . A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr 1990;116:295–300.

    Article  CAS  Google Scholar 

  18. Mandy GT, Moise AA, Smith EO, Hansen TN . Endotracheal continuous positive airway pressure after rescue surfactant therapy. J Perinatol 1998;18:444–448.

    CAS  PubMed  Google Scholar 

  19. Haberman B, Shankaran S, Stevenson DK, et al. Does surfactant (S) and immediate extubation to nasal continuous positive airway pressure (CPAP) reduce use of mechanical ventilation? Pediatr Res 2002;51:349A.

    Google Scholar 

  20. Soll RF, Conner JM, Howard D . Early surfactant replacement in spontaneously breathing premature infants with RDS. Pediatr Res 2003;53:L312.

    Google Scholar 

  21. Escobedo MB, Gunkel JH, Kennedy KA, et al. Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr 2004;144:804–808.

    PubMed  Google Scholar 

  22. Jobe AH, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729.

    Article  CAS  Google Scholar 

  23. D'Angio CT, Khalak R, Stevens TP, et al. Intratracheal surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with RDS requiring nasal CPAP decreases the likelihood of later mechanical ventilation: a randomized controlled trial. Pediatr Res 2003;53:367A.

    Google Scholar 

  24. Stevens TP, Blennow M, Soll RF . Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews 2005;1.

Download references

Acknowledgements

We thank Lawrence Consenstein, Christopher Cox, Kristina Mossgraber and Cassandra Horihan for help in study design and analysis. We also thank the University of Rochester Neonatal Clinical Trials Group for their intellectual input, the neonatal physicians, nurses, and respiratory therapists for their work, and the subjects' parents for their generosity.

Author information

Authors and Affiliations

Authors

Additional information

This research was supported in part by the University of Rochester General Clinical Research Center (5 M01 RR00044). Abbott Laboratories provided the surfactant (Survanta®) used in the study.

Conflict of interest: None of the authors have any potential conflict of interest, real, or perceived.

Supplementary Information accompanies the paper on the Journal of Perinatology website (http://www.nature.com/jp)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reininger, A., Khalak, R., Kendig, J. et al. Surfactant Administration by Transient Intubation in Infants 29 to 35 Weeks' Gestation with Respiratory Distress Syndrome Decreases the Likelihood of Later Mechanical Ventilation: A Randomized Controlled Trial. J Perinatol 25, 703–708 (2005). https://doi.org/10.1038/sj.jp.7211381

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211381

This article is cited by

Search

Quick links